Age and risk of stroke in atrial fibrillation: Evidence for guidelines?

被引:20
作者
Frost, Lars
Andersen, Ljubica Vukelic
Godtfredsen, John
Mortensen, Leif Spange
机构
[1] Aarhus Univ Hosp, Dept Cardiol A, DK-8600 Silkeborg, Denmark
[2] Danish Informat Technol Ctr Educ & Res, UNI C, Aarhus, Denmark
[3] Herlev Univ Hosp, Dept Cardiol, Copenhagen, Denmark
关键词
atrial fibrillation; epidemiology; stroke; stroke risk; age;
D O I
10.1159/000101509
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Aim: Guidelines for the clinical management of patients with atrial fibrillation suggest that treatment strategies for prescribing oral anticoagulant therapy should implicate change at age 60, 65 and 75 years. We examined if there is any threshold concerning risk of stroke by age. Methods: We identified 141,493 subjects, aged 40-89 years, with an incident hospital diagnosis of nonvalvular atrial fibrillation or flutter and no previous or concomitant diagnosis of stroke in the Danish National Registry of Patients from January 1, 1980, to December 31, 2002. The subjects were followed in the Danish National Registry of Patients for the occurrence of an incident diagnosis of stroke of any nature and in the Danish Civil Registration System for emigration and vital status. We examined the risk of stroke by age in men and women using Cox regression models, which included age categorized in intervals, linear splines of age with cut points at age 60 and 75 years, or at age 65 and 75 years. We also analyzed age as a continuous variable in linear and polynomial regression models. Results: During follow-up 15,964 incident strokes were reported to the Danish National Registry of Patients. The risk of stroke increased by increasing age at baseline. We did not find any evidence for a threshold concerning risk of stroke by age, and the best model fit was obtained in a third-order polynomial regression model. Conclusion: The risk of stroke increased gradually by increasing age, and we could not detect any threshold concerning risk of stroke by age. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 31 条
[1]   Antithrombotic therapy in atrial fibrillation [J].
Albers, GW ;
Dalen, JE ;
Laupacis, A ;
Manning, WJ ;
Petersen, P ;
Singer, DE .
CHEST, 2001, 119 (01) :194S-206S
[2]   Statistics notes - The cost of dichotomising continuous variables [J].
Altman, DG ;
Royston, P .
BRITISH MEDICAL JOURNAL, 2006, 332 (7549) :1080-1080
[3]  
Andersen TF, 1999, DAN MED BULL, V46, P263
[4]  
Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273
[5]  
[Anonymous], 2001, CIRCULATION, V104, P2118
[6]   Inflammation as a risk factor for atrial fibrillation [J].
Aviles, RJ ;
Martin, DO ;
Apperson-Hansen, C ;
Houghtaling, PL ;
Rautaharju, P ;
Kronmal, RA ;
Tracy, RP ;
Van Wagoner, DR ;
Psaty, BM ;
Lauer, MS ;
Chung, MK .
CIRCULATION, 2003, 108 (24) :3006-3010
[7]   INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[8]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[9]   WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
EZEKOWITZ, MD ;
BRIDGERS, SL ;
JAMES, KE ;
CARLINER, NH ;
COLLING, CL ;
GORNICK, CC ;
KRAUSESTEINRAUF, H ;
KURTZKE, JF ;
NAZARIAN, SM ;
RADFORD, MJ ;
RICKLES, FR ;
SHABETAI, R ;
DEYKIN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) :1406-1412
[10]   Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation [J].
Friberg, J ;
Gislason, GH ;
Gadsboll, N ;
Rasmussen, JN ;
Rasmussen, S ;
Abildstrom, SZ ;
Kober, L ;
Madsen, M ;
Torp-Pedersen, C .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (02) :173-178